|
US8278079B2
(en)
*
|
2002-11-07 |
2012-10-02 |
Danisco Us Inc. |
BGL6 β-glucosidase and nucleic acids encoding the same
|
|
US20080311095A1
(en)
*
|
2007-05-23 |
2008-12-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for increased transgene expression
|
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
|
ES2465996T3
(es)
*
|
2006-05-25 |
2014-06-09 |
Sangamo Biosciences, Inc. |
Métodos y composiciones para la inactivación genética
|
|
WO2008060510A2
(en)
|
2006-11-13 |
2008-05-22 |
Sangamo Biosciences, Inc. |
Zinc finger nuclease for targeting the human glucocorticoid receptor locus
|
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
|
EP2188384B1
(en)
*
|
2007-09-27 |
2015-07-15 |
Sangamo BioSciences, Inc. |
Rapid in vivo identification of biologically active nucleases
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
AU2008317354B2
(en)
*
|
2007-10-25 |
2014-04-10 |
Ospedale San Raffaele S.R.L. |
Methods and compositions for targeted integration
|
|
MX2010011511A
(es)
|
2008-04-21 |
2011-06-09 |
Danziger Innovations Ltd |
Vectores de expresion viral de planta y uso de los mismos para generar variaciones genotipicas en genomas de plantas.
|
|
CA2725773C
(en)
|
2008-05-28 |
2017-12-05 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
EP2294191B1
(en)
|
2008-06-10 |
2016-09-28 |
Sangamo BioSciences, Inc. |
Methods and compositions for generation of bax- and bak-deficient cell lines
|
|
AU2009283194B2
(en)
|
2008-08-22 |
2014-10-16 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
CN102264915B
(zh)
|
2008-10-29 |
2014-04-16 |
桑格摩生物科学股份有限公司 |
失活谷氨酰胺合成酶基因表达的方法和组合物
|
|
US20110016539A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of neurotransmission-related genes in animals
|
|
US20110023148A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of addiction-related genes in animals
|
|
US20110023156A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Feline genome editing with zinc finger nucleases
|
|
US20110023158A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Bovine genome editing with zinc finger nucleases
|
|
US20110023143A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of neurodevelopmental genes in animals
|
|
US20110023147A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of prion disorder-related genes in animals
|
|
US20110023145A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in autism spectrum disorders
|
|
US20110016541A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of sensory-related genes in animals
|
|
US20110030072A1
(en)
*
|
2008-12-04 |
2011-02-03 |
Sigma-Aldrich Co. |
Genome editing of immunodeficiency genes in animals
|
|
US20110016546A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Porcine genome editing with zinc finger nucleases
|
|
US20110023140A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Rabbit genome editing with zinc finger nucleases
|
|
US20110023151A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of abc transporters
|
|
US20110023152A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of cognition related genes in animals
|
|
US20110023141A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved with parkinson's disease
|
|
AU2009322964B2
(en)
|
2008-12-04 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Genome editing in rats using zinc-finger nucleases
|
|
US20110023146A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in secretase-associated disorders
|
|
US20110016540A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
|
|
US20110023150A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of genes associated with schizophrenia in animals
|
|
US20110023154A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Silkworm genome editing with zinc finger nucleases
|
|
US20110023139A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in cardiovascular disease
|
|
US20110023153A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in alzheimer's disease
|
|
US20110023149A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in tumor suppression in animals
|
|
US20110016543A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in inflammation
|
|
US20110023144A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
|
|
WO2010107493A2
(en)
|
2009-03-20 |
2010-09-23 |
Sangamo Biosciences, Inc. |
Modification of cxcr4 using engineered zinc finger proteins
|
|
CA2756833C
(en)
*
|
2009-04-09 |
2019-11-19 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
|
WO2011002503A1
(en)
|
2009-06-30 |
2011-01-06 |
Sangamo Biosciences, Inc. |
Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
|
|
CA2769262C
(en)
*
|
2009-07-28 |
2019-04-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating trinucleotide repeat disorders
|
|
WO2011048600A1
(en)
|
2009-10-21 |
2011-04-28 |
Danziger Innovations Ltd. |
Generating genotypic variations in plant genomes by gamete infection
|
|
US8956828B2
(en)
*
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
EP2504429B1
(en)
*
|
2009-11-27 |
2016-04-20 |
BASF Plant Science Company GmbH |
Chimeric endonucleases and uses thereof
|
|
US9493827B2
(en)
*
|
2010-01-14 |
2016-11-15 |
Deutsches Krebsforschungszentrum |
Determination of in vivo DNA double-strand break localization and application thereof
|
|
JP5902631B2
(ja)
*
|
2010-01-22 |
2016-04-13 |
ダウ アグロサイエンシィズ エルエルシー |
標的化ゲノム変更
|
|
WO2011097036A1
(en)
|
2010-02-08 |
2011-08-11 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
|
JP2013518602A
(ja)
|
2010-02-09 |
2013-05-23 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
部分的に一本鎖のドナー分子による標的化ゲノム改変
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
PL2566972T3
(pl)
|
2010-05-03 |
2020-06-29 |
Sangamo Therapeutics, Inc. |
Kompozycje do wiązania modułów z motywem palca cynkowego
|
|
EP3156062A1
(en)
|
2010-05-17 |
2017-04-19 |
Sangamo BioSciences, Inc. |
Novel dna-binding proteins and uses thereof
|
|
US20110201118A1
(en)
*
|
2010-06-14 |
2011-08-18 |
Iowa State University Research Foundation, Inc. |
Nuclease activity of tal effector and foki fusion protein
|
|
CA3157027A1
(en)
|
2010-07-21 |
2012-01-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a t-cell receptor gene
|
|
BR112013001685B1
(pt)
*
|
2010-07-23 |
2021-10-13 |
Sigma-Aldrich Co. Llc |
Método para editar pelo menos uma sequência cromossômica endógena em uma célula pela inserção de uma sequência na sequência cromossômica
|
|
WO2012015938A2
(en)
*
|
2010-07-27 |
2012-02-02 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
|
WO2012018726A1
(en)
*
|
2010-08-02 |
2012-02-09 |
Cellectis Sa |
Method for increasing double-strand break-induced gene targeting
|
|
EP3511420B1
(en)
|
2010-09-27 |
2021-04-07 |
Sangamo Therapeutics, Inc. |
Compositions for inhibiting viral entry into cells
|
|
KR101930711B1
(ko)
|
2010-10-12 |
2018-12-19 |
더 칠드런스 호스피탈 오브 필라델피아 |
혈우병 ｂ의 치료를 위한 방법 및 조성물
|
|
ES2713560T3
(es)
|
2010-10-15 |
2019-05-22 |
Fund Centre De Regulacio Genòmica |
Péptidos que tienen dominios de dedos de zinc y usos de estos
|
|
CN102234628A
(zh)
*
|
2011-05-06 |
2011-11-09 |
中国科学院广州生物医药与健康研究院 |
Ccr5缺失型的造血干细胞及其制备方法与应用
|
|
EP2522726A1
(en)
|
2011-05-12 |
2012-11-14 |
Fundació Privada Centre de Regulació Genòmica (CRG) |
Zinc finger nucleases for p53 editing
|
|
US9150847B2
(en)
|
2011-09-21 |
2015-10-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of transgene expression
|
|
EP2758537A4
(en)
*
|
2011-09-23 |
2015-08-12 |
Univ Iowa State Res Found |
MONOERARY TECHNIQUE OF TAL NUCLEASE OR ZINC FINGERUCLEASE FOR DNA MODIFICATION
|
|
US8895264B2
(en)
|
2011-10-27 |
2014-11-25 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the HPRT locus
|
|
HK1200871A1
(en)
|
2011-11-16 |
2015-08-14 |
Sangamo Therapeutics, Inc. |
Modified dna-binding proteins and uses thereof
|
|
WO2013101877A2
(en)
|
2011-12-29 |
2013-07-04 |
Iowa State University Research Foundation, Inc. |
Genetically modified plants with resistance to xanthomonas and other bacterial plant pathogens
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
NZ629427A
(en)
|
2012-02-29 |
2016-04-29 |
Sangamo Biosciences Inc |
Methods and compositions for treating huntington’s disease
|
|
JP6559063B2
(ja)
|
2012-05-07 |
2019-08-14 |
サンガモ セラピューティクス， インコーポレイテッド |
導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物
|
|
LT3401400T
(lt)
|
2012-05-25 |
2019-06-10 |
The Regents Of The University Of California |
Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
EP2872154B1
(en)
|
2012-07-11 |
2017-05-31 |
Sangamo BioSciences, Inc. |
Methods and compositions for delivery of biologics
|
|
US20140072961A1
(en)
*
|
2012-07-11 |
2014-03-13 |
University of Nevada, Las Vegas |
Method of Genome Surgery with Paired, Permeant Endonuclease Excision
|
|
CA2875618C
(en)
|
2012-07-11 |
2021-04-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for the treatment of lysosomal storage diseases
|
|
DK2890780T3
(da)
|
2012-08-29 |
2020-09-21 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
|
|
EP3763810A3
(en)
|
2012-10-10 |
2021-07-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
WO2014081855A1
(en)
*
|
2012-11-20 |
2014-05-30 |
Universite De Montreal |
Methods and compositions for muscular dystrophies
|
|
US9255250B2
(en)
|
2012-12-05 |
2016-02-09 |
Sangamo Bioscience, Inc. |
Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
|
|
EP3135765A1
(en)
|
2012-12-06 |
2017-03-01 |
Sigma-Aldrich Co. LLC |
Crispr-based genome modification and regulation
|
|
EP2958996B1
(en)
|
2013-02-25 |
2019-10-16 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
SG11201507378UA
(en)
|
2013-03-14 |
2015-10-29 |
Caribou Biosciences Inc |
Compositions and methods of nucleic acid-targeting nucleic acids
|
|
EP2975942B1
(en)
|
2013-03-21 |
2018-08-08 |
Sangamo Therapeutics, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
|
JP2016522679A
(ja)
*
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
|
|
CA2910427C
(en)
*
|
2013-05-10 |
2024-02-20 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
EP3730615A3
(en)
|
2013-05-15 |
2020-12-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
CA2920899C
(en)
|
2013-08-28 |
2023-02-28 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
CA2926078C
(en)
|
2013-10-17 |
2021-11-16 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
CN110713995B
(zh)
|
2013-10-17 |
2023-08-01 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
|
AU2014346424B2
(en)
|
2013-11-11 |
2020-09-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating Huntington's Disease
|
|
HUE056436T2
(hu)
|
2013-11-13 |
2022-02-28 |
Childrens Medical Center |
Nukleáz közvetítette génexpresszió-szabályozás
|
|
CA2930877A1
(en)
*
|
2013-11-18 |
2015-05-21 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
|
ES2813367T3
(es)
|
2013-12-09 |
2021-03-23 |
Sangamo Therapeutics Inc |
Métodos y composiciones para ingeniería genómica
|
|
HUE051232T2
(hu)
|
2014-02-03 |
2021-03-01 |
Sangamo Therapeutics Inc |
Béta-talasszémia kezelésére szolgáló eljárások és készítmények
|
|
AU2015218576B2
(en)
|
2014-02-24 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
KR101576728B1
(ko)
*
|
2014-03-06 |
2015-12-10 |
가톨릭대학교 산학협력단 |
면역세포 백신 및 이의 용도
|
|
JP6594891B2
(ja)
|
2014-03-18 |
2019-10-23 |
サンガモ セラピューティクス， インコーポレイテッド |
ジンクフィンガータンパク質発現を調節するための方法および組成物
|
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
|
CN106413760B
(zh)
|
2014-05-08 |
2020-01-14 |
桑格摩生物科学股份有限公司 |
用于治疗亨廷顿病的方法和组合物
|
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
|
EP3151846A4
(en)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for nuclease design
|
|
US9757420B2
(en)
|
2014-07-25 |
2017-09-12 |
Sangamo Therapeutics, Inc. |
Gene editing for HIV gene therapy
|
|
US9816074B2
(en)
|
2014-07-25 |
2017-11-14 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
WO2016037164A1
(en)
|
2014-09-07 |
2016-03-10 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
|
|
HUE055583T2
(hu)
|
2014-09-16 |
2021-12-28 |
Sangamo Therapeutics Inc |
Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben
|
|
CN107106689A
(zh)
|
2014-11-05 |
2017-08-29 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
|
CN112410338A
(zh)
|
2014-11-14 |
2021-02-26 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
IL292999A
(en)
|
2014-11-14 |
2022-07-01 |
Voyager Therapeutics Inc |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
EP3025719B1
(en)
|
2014-11-26 |
2018-09-26 |
Miltenyi Biotec GmbH |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
|
WO2016084084A1
(en)
|
2014-11-27 |
2016-06-02 |
Danziger Innovations Ltd. |
Nucleic acid constructs for genome editing
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
HK1246690A1
(zh)
|
2015-01-21 |
2018-09-14 |
Sangamo Therapeutics, Inc. |
用於鉴定高度特异性核酸酶的方法和组合物
|
|
WO2016128549A1
(en)
|
2015-02-13 |
2016-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
|
|
EP3277805B1
(en)
|
2015-03-31 |
2025-05-07 |
SOHM, Inc. |
Cas 9 retroviral integrase systems for targeted incorporation of a dna sequence into a genome of a cell
|
|
WO2016161446A1
(en)
*
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
CA2988854A1
(en)
|
2015-05-08 |
2016-11-17 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
|
JP6873917B2
(ja)
*
|
2015-05-12 |
2021-05-19 |
サンガモ セラピューティクス， インコーポレイテッド |
ヌクレアーゼ介在性遺伝子発現調節
|
|
CN107614680A
(zh)
*
|
2015-05-14 |
2018-01-19 |
南加利福尼亚大学 |
利用重组核酸内切酶系统的最佳化基因编辑
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
CN108024544B
(zh)
|
2015-07-13 |
2022-04-29 |
桑格摩生物治疗股份有限公司 |
用于核酸酶介导的基因组工程化的递送方法及组合物
|
|
LT3352776T
(lt)
|
2015-09-23 |
2025-07-10 |
Sangamo Therapeutics, Inc. |
Htt represoriai ir jų panaudojimas
|
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
|
CN115141836B
(zh)
|
2015-10-28 |
2024-08-27 |
桑格摩生物治疗股份有限公司 |
肝特异性构建体、因子viii表达盒及其使用方法
|
|
WO2017079428A1
(en)
|
2015-11-04 |
2017-05-11 |
President And Fellows Of Harvard College |
Site specific germline modification
|
|
US10639383B2
(en)
|
2015-11-23 |
2020-05-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
AU2016374253B2
(en)
|
2015-12-18 |
2021-10-21 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the MHC cell receptor
|
|
ES2983043T3
(es)
|
2015-12-18 |
2024-10-21 |
Sangamo Therapeutics Inc |
Alteración dirigida del receptor de células T
|
|
AU2017207818B2
(en)
|
2016-01-15 |
2024-03-28 |
Regents Of The University Of Minnesota |
Methods and compositions for the treatment of neurologic disease
|
|
CN109069568B
(zh)
*
|
2016-02-02 |
2023-07-07 |
桑格摩生物治疗股份有限公司 |
用于连接dna结合结构域和切割结构域的组合物
|
|
SG11201809699XA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
|
KR20220108216A
(ko)
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
|
IL300783B2
(en)
|
2016-08-24 |
2026-03-01 |
Sangamo Therapeutics Inc |
Engineered nucleases with target-specific zinc fingers
|
|
BR112019003100A2
(pt)
|
2016-08-24 |
2019-07-09 |
Sangamo Therapeutics, Inc. |
regulação da expressão gênica usando nucleases manipuladas
|
|
WO2018049009A2
(en)
|
2016-09-07 |
2018-03-15 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
CN110022904B
(zh)
|
2016-10-20 |
2024-04-19 |
桑格摩生物治疗股份有限公司 |
用于治疗法布里病的方法和组合物
|
|
US11020492B2
(en)
|
2016-10-31 |
2021-06-01 |
Sangamo Therapeutics, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
ES2981244T3
(es)
|
2017-04-28 |
2024-10-07 |
Acuitas Therapeutics Inc |
Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
|
|
US11655275B2
(en)
|
2017-05-03 |
2023-05-23 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
SG11201909870SA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
CA3068634A1
(en)
|
2017-06-30 |
2019-01-03 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for adoptive cell therapy for cancer
|
|
CA3068072A1
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for assessing crispr/cas-mediated disruption or excision and crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
|
|
CN110891420B
(zh)
|
2017-07-31 |
2022-06-03 |
瑞泽恩制药公司 |
Cas转基因小鼠胚胎干细胞和小鼠及其应用
|
|
JP2020530990A
(ja)
|
2017-07-31 |
2020-11-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ｉｎ ｖｉｖｏでの外因性ドナー核酸とのＣＲＩＳＰＲ／Ｃａｓ誘導性組換えの評価
|
|
CA3071683A1
(en)
|
2017-08-08 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
Chimeric antigen receptor mediated cell targeting
|
|
MX2020003838A
(es)
|
2017-10-13 |
2020-08-06 |
Selecta Biosciences Inc |
Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral.
|
|
BR112020008568A2
(pt)
|
2017-11-09 |
2020-10-06 |
Sangamo Therapeutics, Inc. |
modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)
|
|
CN111954540A
(zh)
|
2018-02-08 |
2020-11-17 |
桑格摩生物治疗股份有限公司 |
工程化靶标特异性核酸酶
|
|
SG11202007697VA
(en)
|
2018-02-15 |
2020-09-29 |
Memorial Sloan Kettering Cancer Center |
Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
|
|
KR20200139679A
(ko)
|
2018-02-26 |
2020-12-14 |
안톨알엑스, 인크. |
면역관용성 리포솜 및 그의 사용 방법
|
|
KR20240038811A
(ko)
|
2018-03-19 |
2024-03-25 |
리제너론 파마슈티칼스 인코포레이티드 |
CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
|
|
AU2019247199A1
(en)
|
2018-04-05 |
2020-10-15 |
Editas Medicine, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
EP3775238A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
|
US11421007B2
(en)
|
2018-04-18 |
2022-08-23 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (Htt)
|
|
EP3794126A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
EP3841204A4
(en)
|
2018-08-23 |
2022-05-18 |
Sangamo Therapeutics, Inc. |
CHANGED TARGET SPECIFIC BASE EDITORS
|
|
US12398402B2
(en)
|
2018-09-12 |
2025-08-26 |
Fred Hutchinson Cancer Center |
Reducing CD33 expression to selectively protect therapeutic cells
|
|
AU2019344927A1
(en)
|
2018-09-18 |
2021-04-01 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (PD1) specific nucleases
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
WO2020069029A1
(en)
|
2018-09-26 |
2020-04-02 |
Emendobio Inc. |
Novel crispr nucleases
|
|
AU2019358519A1
(en)
*
|
2018-10-11 |
2021-05-27 |
Fondazione Telethon Ets |
Selection by means of artificial transactivators
|
|
EP3867376A1
(en)
|
2018-10-18 |
2021-08-25 |
Intellia Therapeutics, Inc. |
Nucleic acid constructs and methods of use
|
|
BR112021007301A2
(pt)
|
2018-10-18 |
2021-07-27 |
Intellia Therapeutics, Inc. |
composições e métodos para expressar fator ix
|
|
US12583816B2
(en)
|
2018-10-18 |
2026-03-24 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
CA3120570A1
(en)
|
2018-11-28 |
2020-06-04 |
Forty Seven, Inc. |
Genetically modified hspcs resistant to ablation regime
|
|
JP7523449B2
(ja)
|
2019-01-11 |
2024-07-26 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
|
WO2020163379A1
(en)
|
2019-02-05 |
2020-08-13 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
|
WO2020163307A1
(en)
|
2019-02-06 |
2020-08-13 |
Emendobio Inc. |
New engineered high fidelity cas9
|
|
JP7524214B2
(ja)
|
2019-04-03 |
2024-07-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗体コード配列をセーフハーバー遺伝子座に挿入するための方法および組成物
|
|
MX2021013223A
(es)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
|
|
AU2020265741A1
(en)
|
2019-05-01 |
2021-11-25 |
Editas Medicine, Inc. |
Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
|
|
BR112021023594A2
(pt)
|
2019-05-28 |
2022-02-08 |
Selecta Biosciences Inc |
Métodos e composições para resposta imune de vetor de transferência antiviral atenuada
|
|
JP2022539248A
(ja)
|
2019-07-02 |
2022-09-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
組換えａｄ３５ベクター及び関連遺伝子治療改善
|
|
US20230149457A1
(en)
*
|
2019-07-17 |
2023-05-18 |
Case Western Reserve University |
Long lived t cells for treating hiv infection
|
|
US20230416776A1
(en)
|
2019-10-08 |
2023-12-28 |
Regents Of The University Of Minnesota |
Crispr-mediated human genome editing with vectors
|
|
JP7756639B2
(ja)
|
2019-11-08 |
2025-10-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｘ連鎖性若年網膜分離療法のためのｃｒｉｓｐｒおよびａａｖ戦略
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
EP4125348A1
(en)
|
2020-03-23 |
2023-02-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
|
GB202007578D0
(en)
|
2020-05-21 |
2020-07-08 |
Univ Oxford Innovation Ltd |
Hdr enhancers
|
|
WO2021234388A1
(en)
|
2020-05-21 |
2021-11-25 |
Oxford Genetics Limited |
Hdr enhancers
|
|
EP4153741A1
(en)
|
2020-05-21 |
2023-03-29 |
Oxford Genetics Limited |
Hdr enhancers
|
|
GB202007577D0
(en)
|
2020-05-21 |
2020-07-08 |
Oxford Genetics Ltd |
Hdr enhancers
|
|
CN121884957A
(zh)
|
2020-05-22 |
2026-04-17 |
因斯特罗公司 |
使用机器学习模型预测疾病结果
|
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
GB202010075D0
(en)
|
2020-07-01 |
2020-08-12 |
Imp College Innovations Ltd |
Therapeutic nucleic acids, peptides and uses
|
|
US20230374483A1
(en)
|
2020-07-08 |
2023-11-23 |
Regents Of The University Of Minnesota |
Modified hexosaminidase and uses thereof
|
|
JP7798855B2
(ja)
|
2020-07-16 |
2026-01-14 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子に使用するためのカチオン性脂質
|
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
JP2024511414A
(ja)
|
2021-03-23 |
2024-03-13 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球のｃｉｓｈ遺伝子編集及び免疫療法におけるその使用
|
|
WO2023035011A1
(en)
|
2021-09-03 |
2023-03-09 |
North Carolina State University |
Compositions and methods for conferring resistance to geminivirus
|
|
US20230141563A1
(en)
|
2021-10-12 |
2023-05-11 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
|
EP4423119A1
(en)
|
2021-10-27 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for expressing factor ix for hemophilia b therapy
|
|
EP4426832A1
(en)
|
2021-11-03 |
2024-09-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Precise genome editing using retrons
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
US12582104B2
(en)
|
2021-12-08 |
2026-03-24 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023122805A1
(en)
|
2021-12-20 |
2023-06-29 |
Vestaron Corporation |
Sorbitol driven selection pressure method
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
CA3242731A1
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
|
|
EP4476331A2
(en)
|
2022-02-07 |
2024-12-18 |
Ensoma, Inc. |
Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
|
|
EP4475671A1
(en)
|
2022-02-07 |
2024-12-18 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
|
CA3242729A1
(en)
|
2022-02-11 |
2023-08-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for screening 4r tau targeting agents
|
|
US20230357437A1
(en)
|
2022-03-09 |
2023-11-09 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
|
EP4522203A1
(en)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
|
WO2023220035A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
|
EP4522210A1
(en)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
|
KR20250054842A
(ko)
|
2022-07-29 |
2025-04-23 |
리제너론 파마슈티칼스 인코포레이티드 |
뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
CA3265590A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
MODIFIED ANTIBODY-RESISTANT RECEPTORS TO IMPROVE CELL-BASED THERAPIES
|
|
CN120693347A
(zh)
|
2022-11-04 |
2025-09-23 |
瑞泽恩制药公司 |
钙电压门控通道辅助亚基γ1(CACNG1)结合蛋白和CACNG1介导的向骨骼肌的递送
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
CN121002052A
(zh)
|
2023-02-03 |
2025-11-21 |
C3S2 有限公司 |
用于非病毒生产工程化免疫细胞的方法
|
|
WO2024196965A1
(en)
|
2023-03-23 |
2024-09-26 |
Carbon Biosciences, Inc. |
Parvovirus compositions and related methods for gene therapy
|
|
US12383615B2
(en)
|
2023-03-23 |
2025-08-12 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
|
|
GB202311501D0
(en)
|
2023-07-26 |
2023-09-06 |
Imperial College Innovations Ltd |
Zinc finger peptides, encoded nucleic acids, methods and uses
|
|
US20250049896A1
(en)
|
2023-07-28 |
2025-02-13 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
TW202513801A
(zh)
|
2023-07-28 |
2025-04-01 |
美商雷傑納榮製藥公司 |
用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ插入
|
|
KR20260046119A
(ko)
|
2023-07-28 |
2026-04-06 |
리제너론 파마슈티칼스 인코포레이티드 |
단방향 유전자 삽입 동안 도입유전자 발현을 증진시키는 bGH-SV40L 직렬 PolyA의 용도
|
|
WO2025049524A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Cxcr4 antibody-resistant modified receptors
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025128981A1
(en)
|
2023-12-14 |
2025-06-19 |
Sohm, Inc. |
Compositions and methods for genome editing
|
|
WO2025132815A1
(en)
|
2023-12-20 |
2025-06-26 |
Novozymes A/S |
Novel cas nucleases and polynucleotides encoding the same
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
TW202605143A
(zh)
|
2024-05-10 |
2026-02-01 |
美商奇諾治療有限公司 |
表現cd19嵌合抗原受體(car)之基因工程化t細胞及其用於同種異體細胞療法之用途
|
|
WO2025265017A1
(en)
|
2024-06-20 |
2025-12-26 |
Regeneron Pharmaceuticals, Inc. |
Ass1 gene insertion for the treatment of citrullinemia type i
|
|
WO2026072529A1
(en)
|
2024-09-24 |
2026-04-02 |
University Of Florida Research Foundation, Incorporated |
Mettl7a for improved embryo competence
|
|
WO2026072721A1
(en)
|
2024-09-25 |
2026-04-02 |
Carbon Biosciences, Inc. |
Parvovirus compositions and methods for gene therapy
|
|
WO2026073244A1
(en)
|
2024-09-30 |
2026-04-02 |
Ensoma, Inc. |
Constructs for multi-lineage expression of therapeutic agents
|
